BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 12066584)

  • 1. Cost-effectiveness of Helicobacter pylori eradication therapy at a company occupational health clinic in Japan.
    Yamasaki T
    J UOEH; 2002 Jun; 24(2):161-76. PubMed ID: 12066584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decision analysis of histamine H2-receptor antagonist maintenance therapy versus Helicobacter pylori eradication therapy: a randomised controlled trial in patients with continuing pain after duodenal ulcer.
    Tavakoli M; Prach AT; Malek M; Hopwood D; Senior BW; Murray FE
    Pharmacoeconomics; 1999 Oct; 16(4):355-65. PubMed ID: 10623364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eradicating Helicobacter pylori in peptic ulcer disease reduces medical costs in the community.
    Sone Y; Kumada T; Toyoda H; Yokoyama M; Kato M; Asaka M
    Helicobacter; 2008 Oct; 13(5):346-51. PubMed ID: 19250509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immediate eradication of Helicobacter pylori in patients with previously documented peptic ulcer disease: clinical and economic effects.
    Fendrick AM; McCort JT; Chernew ME; Hirth RA; Patel C; Bloom BS
    Am J Gastroenterol; 1997 Nov; 92(11):2017-24. PubMed ID: 9362183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of Helicobacter pylori eradication for the treatment of duodenal ulcer disease in Japan: a decision analysis to assess eradication strategy in comparison with a conventional strategy.
    Habu Y; Inokuchi H; Kiyota K; Hayashi K; Watanabe Y; Kawai K; Stålhammar NO
    J Gastroenterol Hepatol; 1998 Mar; 13(3):280-7. PubMed ID: 9570241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia.
    Gisbert JP; Marcos S; Gisbert JL; Pajares JM
    Eur J Gastroenterol Hepatol; 2001 Nov; 13(11):1303-7. PubMed ID: 11692055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance therapy with H2-receptor antagonist until assessment of Helicobacter pylori eradication can reduce recurrence of peptic ulcer after successful eradication of the organism: prospective randomized controlled trial.
    Murakami K; Sato R; Okimoto T; Watanabe K; Nasu M; Kodama M; Fujioka T
    J Gastroenterol Hepatol; 2006 Jun; 21(6):1048-53. PubMed ID: 16724993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-term endoscopic follow-up for peptic ulcer patients after eradication of H. pylori; comparison with the maintainance therapy by H2-blocker].
    Shirai T; Kurumada T; Kouda K; Asano K; Takagi A; Harasawa S; Miwa T
    Nihon Rinsho; 1999 Jan; 57(1):157-61. PubMed ID: 10036955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost analysis of a Helicobacter pylori eradication strategy in a large health maintenance organization.
    Levin TR; Schmittdiel JA; Henning JM; Kunz K; Henke CJ; Colby CJ; Selby JV
    Am J Gastroenterol; 1998 May; 93(5):743-7. PubMed ID: 9625120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis.
    Ford AC; Delaney BC; Forman D; Moayyedi P
    Am J Gastroenterol; 2004 Sep; 99(9):1833-55. PubMed ID: 15330927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial of test-and-treat strategy for Helicobacter pylori: clinical outcomes and health care costs in a managed care population receiving long-term acid suppression therapy for physician-diagnosed peptic ulcer disease.
    Allison JE; Hurley LB; Hiatt RA; Levin TR; Ackerson LM; Lieu TA
    Arch Intern Med; 2003 May; 163(10):1165-71. PubMed ID: 12767952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. H2-antagonist maintenance therapy versus Helicobacter pylori eradication in patients with chronic duodenal ulcer disease: a prospective study.
    Prach AT; Malek M; Tavakoli M; Hopwood D; Senior BW; Murray FE
    Aliment Pharmacol Ther; 1998 Sep; 12(9):873-80. PubMed ID: 9768530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eradication of Helicobacter pylori does not decrease the long-term use of acid-suppressive medication.
    Tan AC; Hartog GD; Mulder CJ
    Aliment Pharmacol Ther; 1999 Nov; 13(11):1519-22. PubMed ID: 10571610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance treatment is not necessary after Helicobacter pylori eradication and healing of bleeding peptic ulcer: a 5-year prospective, randomized, controlled study.
    Liu CC; Lee CL; Chan CC; Tu TC; Liao CC; Wu CH; Chen TK
    Arch Intern Med; 2003 Sep; 163(17):2020-4. PubMed ID: 14504114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacoeconomics in the therapy of peptic ulcer].
    Tesar T; Foltán V; Huorka M
    Ceska Slov Farm; 2002 Mar; 51(2):78-83. PubMed ID: 11928281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Helicobacter pylori eradication therapy on risk of hospitalization for a major ulcer event.
    Hsiao FY; Tsai YW; Wen YW; Kuo KN; Tsai CR; Huang WF
    Pharmacotherapy; 2011 Mar; 31(3):239-47. PubMed ID: 21361733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Helicobacter pylori eradication prior to initiation of long-term non-steroidal anti-inflammatory drug therapy in Chinese patients-a cost-effectiveness analysis.
    You JH; Lau W; Lee IY; Yung M; Ching JY; Chan FK; Lee KK
    Int J Clin Pharmacol Ther; 2006 Apr; 44(4):149-53. PubMed ID: 16625983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of competing strategies for the prevention of recurrent peptic ulcer hemorrhage.
    Ofman J; Wallace J; Badamgarav E; Chiou CF; Henning J; Laine L
    Am J Gastroenterol; 2002 Aug; 97(8):1941-50. PubMed ID: 12190158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eradication rates of helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease.
    Chung SJ; Lee DH; Kim N; Jung SH; Kim JW; Hwang JH; Park YS; Lee KH; Jung HC; Song IS
    Hepatogastroenterology; 2007 Jun; 54(76):1293-6. PubMed ID: 17629092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bismuth-based combination therapy for Helicobacter pylori-associated peptic ulcer disease (metronidazole for eradication, ranitidine for pain).
    Tefera S; Berstad A; Bang CJ; Nysaeter G; Hatlebakk JG; Olafsson S; Nesje LB; Hausken T; Berstad K; Hundal O
    Am J Gastroenterol; 1996 May; 91(5):935-41. PubMed ID: 8633584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.